A Randomized, Sham Surgery Controlled, Double-blind, Multi-center, Phase 2 Clinical Trial, Evaluating the Efficacy and Safety of VY-AADC02 in Moderate to Advanced Parkinson’s Disease Patients With Motor Fluctuations

1. Males and females, 40 to 75 years of age (inclusive)

2. Diagnosis of PD, consistent with United Kingdom Brain Bank Criteria

3. Motor responsiveness to dopaminergic therapy, demonstrated by improvement in MDS-UPDRS
III score

4. Disease duration from diagnosis of ≥4 years

5. An average of ≥3 hours of OFF time (ie, periods of insufficient control of motor PD
symptoms) per day over 3 consecutive days as confirmed by the PD Diary

6. A stable, optimal regimen of Parkinson’s medications including levodopa for at least
weeks prior to screening evaluation. Participants must have a minimum duration of
levodopa treatment of ≥1 year

7. In the judgment of the Investigator, stable Parkinson’s features and symptoms for at
least 4 weeks prior to screening evaluation

8. Agrees to defer any elective neurological surgery, including deep brain stimulation or
ablation procedure for PD, levodopa or apomorphine infusion, or the addition of new
dopaminergic formulations until after the study is completed, if medically appropriate

9. Ability to travel to study visits

Key Exclusion Criteria:

1. Atypical or secondary parkinsonism, including but not limited to symptoms believed to
be due to trauma, brain tumor, infection, cerebrovascular disease, other neurological
disease, or to drugs, chemicals, or toxins, as determined by the Investigator

2. MoCA score <26 3. New or unstable psychiatric conditions (psychosis, depression) within 1 year of screening 4. Brain imaging abnormalities in the striatum or other regions that would substantially increase risk of surgery 5. Contraindication to MRI and/or gadolinium-based contrast agents 6. Prior brain surgery, infusion therapies or planned treatments that could complicate the study procedure or negatively impact study evaluations as determined from participant interview, screening MRI, or medical records 7. History of malignancy other than treated carcinoma in situ within 3 years of screening evaluation 8. Prior gene transfer, current treatment with any investigational agent (drug or device) within 2 months of screening evaluation, or participation or plans to participate in another research study 9. Severe, biphasic and/or uncontrolled dyskinesia 10. Disabling or uncontrolled impulse control disorders